Expression of messenger molecules and receptors in rat and human sphenopalatine ganglion indicating therapeutic targets
© The Author(s). 2016
Received: 1 August 2016
Accepted: 9 August 2016
Published: 1 September 2016
The Erratum to this article has been published in The Journal of Headache and Pain 2016 17:86
Migraine and Cluster Headache (CH) are two primary headaches with severe disease burden. The disease expression and the mechanisms involved are poorly known. In some attacks of migraine and in most attacks of CH, there is a release of vasoactive intestinal peptide (VIP) originating from parasympathetic cranial ganglia such as the sphenopalatine ganglion (SPG). Patients suffering from these diseases are often deprived of effective drugs. The aim of the study was to examine the localization of the botulinum toxin receptor element synaptic vesicle glycoprotein 2A (SV-2A) and the vesicular docking protein synaptosomal-associated protein 25 (SNAP25) in human and rat SPG. Additionally the expression of the neurotransmitters pituitary adenylate cyclase activating polypeptide (PACAP-38), nitric oxide synthase (nNOS), VIP and 5-hydroxttryptamine subtype receptors (5-HT1B,1D,1F) were examined.
SPG from adult male rats and from humans, the later removed at autopsy, were prepared for immunohistochemistry using specific antibodies against neurotransmitters, 5-HT1B,1D,1F receptors, and botulinum toxin receptor elements.
We found that the selected neurotransmitters and 5-HT receptors were expressed in rat and human SPG. In addition, we found SV2-A and SNAP25 expression in both rat and human SPG. We report that all three 5-HT receptors studied occur in neurons and satellite glial cells (SGCs) of the SPG. 5-HT1B receptors were in addition found in the walls of intraganglionic blood vessels.
Recent focus on the SPG has emphasized the role of parasympathetic mechanisms in the pathophysiology of mainly CH. The development of next generation’s drugs and treatment of cranial parasympathetic symptoms, mediated through the SPG, can be modulated by treatment with BoNT-A and 5-HT receptor agonists.
Migraine and Cluster Headache (CH) are two primary headaches with severe disease burden. In particular, CH is an extremely painful disorder characterized by periods (clusters) of recurrent, unilateral attacks of excruciating pain with a retro-orbital maximum and attacks lasting from 15–180 min . CH usually appears between 20 and 40 years of age and during its active phase the attacks occur from once every second day to 8 times a day. Most patients show ipsilateral symptoms such as conjunctival injection, lacrimation, nasal congestion, rhinorrhoea and forehead/facial sweating, indicating an ipsilateral parasympathetic dysfunction which has been proven by co-release of the parasympathetic messenger molecule VIP .
The mechanisms involved in migraine and CH are considered to differ but also share some aspects . Cranial autonomic symptoms (CAS), i.e. parasympathetic symptoms, occur in both migraine and CH patients [4–6], indicating involvement of the trigemino-autonomic reflex with increased parasympathetic outflow [5–7], mediated through the sphenopalatine ganglion (SPG) [8, 9]. Markedly raised levels of VIP and, in particular, calcitonin gene-related protein (CGRP) have been measured during spontaneous CH attacks. These findings were considered as evidence of involvement of the cranial parasympathetic nervous system . In human SPG the parasympathetic signaling transmitters in neural cell bodies consist mainly of VIP, PACAP, acetylcholine (ACh) and NOS .
Onabotulinumtoxin A (BoNT-A), more commonly known by the trade name Botox®, comes from Clostridium botulinum. It works by blocking the release of the neurotransmitter ACh, which has been found in SPG , by cleaving SNAP25, a protein necessary for ACh release from vesicles in nerve endings . However, it is unknown if SNAP25, and SV-2A, are expressed in the SPG. A previous study from our group has shown the presence of SV-2A and SNAP25 in rat trigeminal ganglion (TG) . Incubation with BoNT-A was shown to reduce the inflammation response elicited by organ culture of the TG.
Triptans are 5-hydroxytryptamine (5-HT) receptor agonists with a high affinity for the 5-HT1B/1D/1F receptors, which generally are effective for aborting headache attacks of both migraine and CH. The multiple mechanism of action for 5-HT1B/1D receptors includes vasoconstriction, inhibition of the release of vasoactive neurotransmitters by trigeminal nerves as well as inhibition of nociceptive neurotransmission [13, 14]. 5-HT1F receptors is characterized by lack of vasoconstrictive properties . 5-HT1B,1D receptors have been localized in the human TG [14–16]. Activation of those receptors seems to be one of the triptans modes of action. Early clinical studies showed effects in CH , thus triptans might have a direct effect on human SPG.
The aim of the present work was to examine if rat and human SPG contain the SV2-A and SNAP25 proteins and, by extension, if BoNT-A might have a mechanism of action in SPG. Secondly, we aimed at investigating the expression of 5-HT1B,1D,1F receptors and the SPG neurotransmitters (PACAP-38, nNOS and VIP). This will provide novel and greater understanding of the action mechanisms in the SPG and could increase the possibility for future drug developments for CH.
Wistar or Sprague–Dawley male rats (n Wistar = 9, n Spraque-Dawley = 10, weight = approx. 250 g) were euthanized by CO2 inhalation followed by decapitation. The SPG was carefully dissected out, close to the time of euthanasia, by initially making an incision over the zygomatic bone. The zygomatic bone was cut at both extremities and removed. The exposed deep masseter muscle was removed. The fifth cranial nerve trunk was revealed, carefully cut, and pulled posteriorly. The SPG, situated against the dorsal part of the maxillary bone, is thereby disclosed. The entire ganglion was carefully dissected and placed in 4 % paraformaldehyde for 2–4 h, followed by incubation overnight in Sörensen’s phosphate buffer (pH 7.2) containing 10 % and 25 % sucrose in turn. Thereafter, the tissue was embedded in Yazulla embedding medium (30 % egg albumin and 3 % gelatin in distilled water) and 10 μm cryosections were cut in a cryostat (Thermo Scientific Microm HM560). The sections were stored at −20 °C until use.
The human SPG was collected at autopsy, within 48 h post-mortem, from three patients. The patients were without disorders related to the central nervous system. The specimens were fixed in 4 % paraformaldehyde followed by sucrose-cryoprotection in 10 % sucrose Tyrode solution. The tissue samples were kept at −80 °C until embedding and cryo-sectioning. The study followed the guidelines of the European Communities Council (86/609/ECC) and was approved by the Committee of the Animal Research of University of Szeged (I-74-12/2012) and the Scientific Ethics Committee for Animal Research of the Protection of Animals Advisory Board (XI./352/2012). The rat study was approved by the Regional Ethical Committee on Animal Research, Malmö/Lund, Sweden. (M43-07).
Cryosections of rat and human SPG were stained using Hematoxylin (Htx) and Eosin dyes (Htx 4 min, Eosin 1 min). The staining was done in order to examine the morphology and condition of the tissue.
Overview of the primary antibodies
Human and rat PACAP-38
Peninsula Laboratories, LLC, San Carlos, CA, USA
NOS derived from brain
Sigma Aldrich, St. Louis, MO, USA
C-terminus of mouse VIP
Santa Cruz Biotechnology, Santa Cruz, CA, USA
N-terminus of human SNAP-25
Sigma-Aldrich, St. Louis, MO, USA
Amino acids 1–100 of rat SV2A
Abcam, Cambridge, UK
Amino acids 8–26 and 263–278 of 5HT1B
Abcam, Cambridge, UK
Amino acids 1–18 and 251–267 of rat 5HT1D
Abcam, Cambridge, UK
N-terminus extracellular domain of human 5HT1F
Acris Antibodies, San Diego, CA, USA
Overview of the secondary antibodies
Alexa Flour 488
Invitrogen, CA, USA
Alexa Flour 594
Invitrogen, CA, USA
Alexa Flour 594
Jackson Immunoresearch Laboratories, Inc., West Grove, PA, USA
Jackson Immunoresearch Laboratories, Inc., West Grove, PA, USA
Cayman Chemical, Ann Arbor, MI, USA
Double stainings were exclusively performed in rat SPG. The protocol described above was repeated twice and done sequentially. Each staining was performed three times to ensure reproducibility. Omission of primary antibodies served as negative controls. The sections were examined in an epifluorescence microscope (Nikon 80i, Tokyo, Japan) equipped with a Nikon DS-2MV camera. Finally, images were processed using Adobe Photoshop CS3 (v0.0 Adobe Systems, Mountain View, CA).
Hematoxylin Eosin staining
The 5-HT1B receptor expression was found in numerous neurons and fibers, in addition to the vessel walls (Fig. 2d). 5-HT1D and 5-HT1F immunoreactivities were seen in many neurons and nerve fibers, but not in the vessel walls (Fig. 2e and f).
SNAP25 and SV2-A
SNAP25 immunoreactivity was found in most neurons in the same granular pattern as described for VIP above, but not in SGCs. In addition, nerve fibers were immunoreactive (Fig. 2g). SV2-A immunoreactivity was only found in the SGCs (Fig. 2h).
Individual differences were observed between the human samples in all stainings; two of the three specimens needed antigen retrieval to get the antibodies to recognize the antigen. In addition, many neurons in the human material contained intense autofluorescent lipofuscin in their cytoplasm
5-HT1B immunoreactivity was found in most neurons, in some fibers and in vessel walls (Fig. 5d and e). 5-HT1D immunoreactivity was seen in neurons and fibers (Fig. 5f and g). 5-HT1F immunoreactivity was not observed in the human material (using the available antibodies).
SNAP25 and SV2-A
The present study is the first to examine the co-expression of signalling molecules and receptor elements in human and rat SPG. It is well known that triptans have clinically positive effects on acute pain in CH . Thus, we asked the question if 5-HT1B, 5-HT1D and 5-HT1F receptors are expressed in neurons and SGCs in SPG. Importantly, we report that 5-HT1B, 5-HT1D and 5-HT1F receptors are expressed on most neurons in the rat SPG, which correlates well with the clinical effectiveness of triptans in CH. Here we demonstrate that all three 5-HT receptor subtypes occur in neurons and SGCs of the rat SPG. However, the 5-HT1F receptor was only found in rodent material, possibly due to the antigenic properties of the used antibody. In addition 5-HT1B receptors occur in the intraganglionic blood vessels, putatively indicating a possible vasomotor role. Previous studies have revealed expression of the parasympathetic signaling transmitters VIP, PACAP and nNOS in rat  and human  SPG. The results in the present study are in concert with these earlier studies. We found that both species contain SV2-A and SNAP25, elements involved in ACh neurotransmission, which has not been described earlier, however with a mixed expression. In rat, SNAP25 was expressed in neurons and fibers, but with SV2-A in the SGCs. In humans, SNAP25 was expressed in the SGCs, but SV2-A in the neurons. SNAP25 was mainly seen in the SGCs, while in man the neurons expressed Botox receptors elements SV2-A (opposite in rat). This could indicate that some effect of BoNT-A could occur in SPG provided it reaches this structure. The anatomical proximity of facial/temporal injection sites of BoNT-A in the PREEMPT protocol is much closer to the SPG than to the TG. The significance of the differential expression of SNAP25 and SV2-A is unclear but perhaps the localization of the receptor elements might suggest a potential target site of botulinum toxin if it has access to the receptor site.
Treatment with BoNT-A in adults with chronic migraine (CM) has shown safety and efficacy [20, 21]. Pilot studies of SPG injection of BoNT-A for treatment of CM as well as in chronic CH (CCH) have showed promising results [22, 23]. A previous study has shown presence of SV-2A and SNAP25 protein with same location in the TG . The present results illustrate a possible site/mechanism of action for BoNT-A in CH. There is however no data available for an effect of BoNT-A in CH. The work provides anatomical rationale for this possibility, and given the proximity of the SPG to injection sites used in BoNT-A therapy it might be considered at least. Recent work has focused on neuromodulation of the SPG using e.g. specific SPG stimulation [24, 25].
An issue for the present work is if BoNT-A has a theoretical possibility to work as medical prophylaxis in CH. Earlier studies have shown varying results regarding BoNT-A as prophylactic treatment for CH. Twelve CCH patients were included in an open study where BoNT-A was given as an add-on therapy, i.e. prior prophylactic medication was continued . BoNT-A was injected according to a standardised protocol, ipsilateral to the pain. Four of the twelve patients showed improvement . A pilot study where BoNT-A was injected towards the SPG in CCH patients showed at least 50 % reduction of attack frequency in five out of ten patients . So far, no randomised, placebo-controlled study regarding BoNT-A and treatment of CH has been performed.
Triptans were early found to abort CH attacks [28–30]. It was not until fairly recently that Ivanusic (2011) reported 5-HT1D receptor immunoreactivity in nerve terminals around neurons in the rat SPG. These fibers were all CGRP positive and thus sensory in nature. They were traced back to the TG. Csati et al. (2012) showed CGRP positive fibers also in the human SPG, which agrees well with the present study.
Triptans are 5-HT1B/1D receptor agonists with high affinity for 5-HT1B/1D receptors, which are generally effective for aborting attacks in both migraine and CH. The multiple mechanism of action for 5-HT1B/1D receptors includes vasoconstriction, inhibition of the release of vasoactive neuropeptides by trigeminal nerves as well as inhibition of nociceptive neurotransmission [13, 14]. Both 5-HT1B/1D receptors have been localized in the human TG [14, 16]. Activation of those receptors seems to be one of the triptans modes of action. Triptans might have a direct effect on human SPG. So far, the issue has to be answered. We showed 5-HT1B and 5-HT1D immunoreactivity in SPG neurons, which suggests a role in modifying the activity in SPG. The variability in the 5-HT1F expression is likely due to low specificity of these antibodies species. This issue is under current development.
Some limitations of our study need to be addressed. The human material is restricted to three SPG obtained at autopsy, due to difficulties to obtain those structures. Further, although the material has been carefully processed, we cannot exclude postmortem changes. In addition, our findings are purely anatomical and the question as to function may be addressed in subsequent work.
Theoretically, our work provides anatomical indication, that both triptans and BoNT-A may have an effect on the SPG. Further randomised, placebo-controlled studies regarding especially BoNT-A treatment of CH are warranted. In addition this study also provides evidence for triptan effects in the SPG.
Supported by the Swedish Research Council (grant no 5958).
LE designed the study. FB dissected the rats. SF and KW carried out the immunohistochemistry. AS wrote the first draft of the manuscript and all authors participated in the writing process. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;9:629–808Google Scholar
- Goadsby PJ, Edvinsson L (1994) Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 117(Pt 3):427–434View ArticlePubMedGoogle Scholar
- Matharu M, May A (2008) Functional and structural neuroimaging in trigeminal autonomic cephalalgias. Curr Pain Headache Rep 12:132–7View ArticlePubMedGoogle Scholar
- Lai T, Fuh JL, Wang SJ (2009) Cranial autonomic symptoms in migraine: characteristics and comparison with cluster headache. J Neurol Neurosurg Psychiatry 80(10):1116–9View ArticlePubMedGoogle Scholar
- Obermann M, Yoon MS, Dommes P et al (2007) Prevalence of trigeminal autonomic symptoms in migraine: a population-based study. Cephalagia 27:504–9View ArticleGoogle Scholar
- Barbanti P, Fabbrini G, Burs B et al (2002) Unilateral cranial autonomic symptoms in migraine. Cephalagia 22:256–9View ArticleGoogle Scholar
- Dora B (2003) Migraine with cranial autonomic features and strict unilaterality. Cephalagia 23:561–2View ArticleGoogle Scholar
- Schoenen J, Jensen R, Lanteri-Minet M, Lainez MJA, Gaul C, Goodman AM, Caparso A, May A (2013) Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study. Cephalagia 33:816–30View ArticleGoogle Scholar
- Bahra A, May A, Goadsby PJ (2002) Cluster headache:a prospective clinical study with diagnostic implica-tions. Neurology 58:354–61View ArticlePubMedGoogle Scholar
- Edvinsson L, Uddman R (2005) Neurobiology in primary headaches. Brain Res Rev 48(3):438–56View ArticlePubMedGoogle Scholar
- Edvinsson J, Warfvinge K, Edvinsson L (2015) Modulation of inflammatory mediators in the trigeminal ganglion by botulinum neurotoxin type A: an organ culture study. J Headache Pain 16:555View ArticlePubMedGoogle Scholar
- Humeau Y, Doussau F, Grant NJ, Poulain B (2000) How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 82:427–46View ArticlePubMedGoogle Scholar
- Goadsby P, Hargreaves RJ (2000) Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan. Neurology 55:S8–14PubMedGoogle Scholar
- Tepper S, Rapoport AM, Sheftell FD (2002) Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 59:1084–8View ArticlePubMedGoogle Scholar
- Mitsikostas D, Tfelt-Hansen P (2012) Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future. Cent Nerv Syst Agents Med Chem 12(4):241–9View ArticlePubMedGoogle Scholar
- Hou M, Kanje M, Longmore J, Tajti J, Uddman R, Edvinsson L (2001) 5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase. Brain Res 909:112–120View ArticlePubMedGoogle Scholar
- May A (2005) Cluster headache: pathogenesis, diagnosis, and management. Lancet 366(9488):843–855View ArticlePubMedGoogle Scholar
- Csati A, Tajti J, Kuris A, Tuka B, Edvinsson L, Warfvinge K (2012) Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion. Neuroscience 202:158–168View ArticlePubMedGoogle Scholar
- Uddman R, Tajiti J, Möller S, Sundler F, Edvinsson L (1999) Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res 826:193–199View ArticlePubMedGoogle Scholar
- Aurora S, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30(7):793–803View ArticlePubMedGoogle Scholar
- Diener H, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30(7):804–14View ArticlePubMedGoogle Scholar
- Bratbak D, Nordgård S, Stovner LJ, Linde M, Folvik M, Bugten V, Tronvik E (2016) Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache. Cephalagia 36(6):503–9View ArticleGoogle Scholar
- Bratbak D, Nordgård S, Stovner LJ, Linde M, Dodick DW, Aschehoug I, Folvik M, Tronvik E. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalagia 2016Google Scholar
- Khan S, Schoenen J, Ashina M (2014) Sphenopalatine ganglion neuromodulation in migraine: what is the rationale? Cephalagia 5:382–91View ArticleGoogle Scholar
- Jürgens T, Barloese M, May A, Láinez JM, Schoenen J, Gaul C, Goodman AM, Caparso A, Jensen RH. Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. Cephalagia 2016:Epub ahead of print. Google Scholar
- Sostak P, Krause P, Förderreuther S, Reinisch V, Straube A (2007) Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain 8:236–241View ArticlePubMedPubMed CentralGoogle Scholar
- Bratbak D, Nordgård S, Stovner LJ, Linde M, Folvik M, Bugten V, Tronvik E. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache. Cephalagia 2015Google Scholar
- Ekbom K, Krabbe A, Micieli G, Prusinski A, Cole JA, Pilgrim AJ, Noronha D, Micelli G (1995) Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-term Study Group. Cephalagia 15(5):446Google Scholar
- Ekbom K, Monstad I, Prusinski A, Cole JA, Pilgrim AJ, Noronha D (1993) Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparision study. Acta Neurol Scand 88:63–69View ArticlePubMedGoogle Scholar
- Göbel H, Lindner V, Heinze A, Ribbat M, Deuschl G (1998) Acute therapy for cluster headache with sumatriptan: findings of a one-year long-term study. Neuorolgy 51:908–11View ArticleGoogle Scholar